About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Tennessee | 20,239 Studies Near You | Clareo Health

Clinical Trials LocationsTennessee

Clinical Trials in Tennessee

Discover 20,239 clinical trials near Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11321-11340 of 20,239 trials

COMPLETEDPhase 429 miles

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

NCT00640809

To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole

Bowel Diseases, Inflammatory

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.408 participantsStarted Oct 2003

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +9 more locations

COMPLETEDPhase 429 miles

Mild To Moderate Erectile Dysfunction Study

NCT00137072

Safety/Efficacy of 100-mg Viagra at 8 hours post dose in men with mild to moderate erectile dysfunction

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.355 participantsStarted Apr 2005

Birmingham, Alabama, United States • Homewood, Alabama, United States • Hoover, Alabama, United States +30 more locations

Find Trials by Condition in Tennessee

Breast Cancerin Tennessee Lung Cancerin Tennessee Prostate Cancerin Tennessee Colorectal Cancerin Tennessee Melanomain Tennessee Leukemiain Tennessee Lymphomain Tennessee Pancreatic Cancerin Tennessee Ovarian Cancerin Tennessee Brain Cancerin Tennessee

Data from ClinicalTrials.govTerms

UNKNOWNPhase 129 miles

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).

Breast CancerGastric CancerSolid Tumors+1 more

Hengrui Therapeutics, Inc.50 participantsStarted Jun 2015

Orange, California, United States • Sacramento, California, United States • Sarasota, Florida, United States +7 more locations

COMPLETEDPhase 329 miles

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605

To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day \[TID\]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment in subjects with pulmonary arterial hypertension who are aged 18 years and over. To investigate the plasma concentration-effect relationship and to determine the population pharmacokinetic (PK) parameters.

Hypertension, Pulmonary

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.275 participantsStarted Oct 2002

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +65 more locations

COMPLETEDPhase 429 miles

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635

Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects with Dry Eye Disease

Dry Eye Disease

Toyos Clinic19 participantsStarted Jul 2018

Nashville, Tennessee, United States

COMPLETEDPhase 271 miles

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.

Sexual Dysfunctions, PsychologicalSexual Arousal Disorder

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.267 participantsStarted Jan 2003

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +79 more locations

COMPLETEDPhase 471 miles

A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes

NCT00645268

To determine the effect on erectile function in a population of type 2 diabetic men with erectile dysfunction who have undergone the following treatment regimen: pre-treatment with a daily dose of double-blind sildenafil versus placebo for 4 weeks (Phase I) followed by an as-needed, flexible-dose, open-label treatment phase with sildenafil for 12 weeks (Phase II). To assess safety and tolerability of this dosing regimen and to investigate its effects on endothelial function and subject's responses to the Self-Esteem And Relationship (SEAR) questionnaire.

Erectile DysfunctionDiabetes Mellitus, Type 2

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.300 participantsStarted Dec 2002

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Beverly Hills, California, United States +26 more locations

COMPLETEDPhase 371 miles

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362

This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.

Neuropathic Pain

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.542 participantsStarted Oct 2012

Huntsville, Alabama, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +153 more locations

COMPLETEDPhase 3141 miles

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03719612

This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.

Cardiac Disease

Lantheus Medical Imaging160 participantsStarted Dec 2018

Tucson, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +12 more locations

COMPLETEDPhase 3154 miles

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456

The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.

Hereditary Angioedema Types I and II

CSL Behring90 participantsStarted Jan 2014

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Bell Gardens, California, United States +36 more locations

COMPLETEDPhase 2154 miles

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

NCT02951195

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

Cystic Fibrosis

Vertex Pharmaceuticals Incorporated80 participantsStarted Nov 2016

Birmingham, Alabama, United States • La Jolla, California, United States • Los Angeles, California, United States +13 more locations

TERMINATEDPhase 3156 miles

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

NCT02137837

This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.

SWOG Cancer Research Network37 participantsStarted May 2014

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +220 more locations

TERMINATEDPhase 2190 miles

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915

This is a Phase 2b double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 versus placebo in women with PCOS.

Polycystic Ovary Syndrome (PCOS)

Millendo Therapeutics US, Inc.55 participantsStarted Jul 2016

Phoenix, Arizona, United States • Jonesboro, Arkansas, United States • Oceanside, California, United States +28 more locations

TERMINATEDPhase 3190 miles

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217

The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.377 participantsStarted Apr 2010

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +60 more locations

COMPLETED190 miles

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140

This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tuberculosis infection (tuberculin skin test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) and will examine the rates of positive results among the cohort. This study will also determine the risk and rate of progression to active TB disease, overall and by the results of the three tests.

Latent Tuberculosis InfectionTuberculosis

Centers for Disease Control and Prevention21,334 participantsStarted Oct 2012

Phoenix, Arizona, United States • Richmond, California, United States • Denver, Colorado, United States +7 more locations

COMPLETEDPhase 3277 miles

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874

Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.

Pulmonary Arterial Hypertension

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.234 participantsStarted Jan 2004

Palo Alto, California, United States • Palo Alto, California, United States • Stanford, California, United States +36 more locations

COMPLETED512 miles

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457

This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.

22q11 Deletion SyndromeDiGeorge SyndromeTrisomy 21+8 more

Natera, Inc.20,960 participantsStarted Apr 2015

San Francisco, California, United States • Camden, New Jersey, United States • Mount Laurel, New Jersey, United States +18 more locations

TERMINATEDPhase 1646 miles

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200

This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.

Breast CancerNon Small Cell Lung CancerGastroEsophageal Cancer+1 more

ADC Therapeutics S.A.21 participantsStarted May 2017

Palo Alto, California, United States • Buffalo, New York, United States • New York, New York, United States +2 more locations

TERMINATEDPhase 3768 miles

Pregabalin Trial In HIV Neuropathic Pain

NCT01145417

This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.

HIV-1 InfectionNeuropathic Pain

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.217 participantsStarted Jul 2010

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Burbank, California, United States +26 more locations

COMPLETEDPhase 31273 miles

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

NCT00280059

The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.

Epilepsy, Partial

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.660 participantsStarted Aug 2006

Bruges, Belgium • Brussels, Belgium • Leuven, Belgium +99 more locations

PreviousPage 567 of 1012Next

Diabetes

in Tennessee

Heart Diseasein Tennessee